Literature DB >> 15458531

Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma.

Maryam Asgari1, Emily White, Mary-Margaret Chren.   

Abstract

BACKGROUND: Nonsteroidal anti-inflammatory drugs are widely reported to inhibit carcinogenesis.
OBJECTIVE: The objective was to review the literature on nonsteroidal anti-inflammatory drugs in the prevention and treatment of cancer as it pertains to cutaneous squamous cell carcinoma.
METHODS: We searched MEDLINE and performed a review of all published data on nonsteroidal anti-inflammatory drugs and cutaneous oncogenesis.
RESULTS: In vitro and animal data strongly suggest a role for cyclooxygenase-2 in the formation of actinic keratoses and squamous cell carcinomas. Further observational studies and clinical trials are needed to assess their putative role in chemoprevention.
CONCLUSIONS: Nonsteroidal anti-inflammatory drugs have activity against squamous cell carcinomas in vitro and in animal models, as well as in precursor lesions of squamous cell carcinomas. Human trials using selective cyclooxygenase-2 inhibitors are currently in progress and should offer exciting information regarding the chemopreventative function of nonsteroidal anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15458531     DOI: 10.1111/j.1524-4725.2004.30407.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  11 in total

1.  Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.

Authors:  Joanne M Jeter; Clara Curiel-Lewandrowski; Steven P Stratton; Paul B Myrdal; James A Warneke; Janine G Einspahr; Hubert G Bartels; Michael Yozwiak; Yira Bermudez; Chengcheng Hu; Peter Bartels; David S Alberts
Journal:  Cancer Prev Res (Phila)       Date:  2015-12-28

2.  Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.

Authors:  Jean Y Tang; Michelle Aszterbaum; Mohammad Athar; Franco Barsanti; Carol Cappola; Nini Estevez; Jennifer Hebert; Jimmy Hwang; Yefim Khaimskiy; Arianna Kim; Ying Lu; Po-Lin So; Xiuwei Tang; Michael A Kohn; Charles E McCulloch; Levy Kopelovich; David R Bickers; Ervin H Epstein
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

3.  Role of cytokines in experimentally induced lung cancer and chemoprevention by COX-2 selective inhibitor, etoricoxib.

Authors:  Neeti Nadda; Shruti Setia; Vivek Vaish; Sankar Nath Sanyal
Journal:  Mol Cell Biochem       Date:  2012-09-19       Impact factor: 3.396

4.  Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma.

Authors:  Maryam M Asgari; Mary-Margaret Chren; E Margaret Warton; Gary D Friedman; Emily White
Journal:  Arch Dermatol       Date:  2010-02-15

5.  COX-2 inhibitors show no preventive effect in the development of skin cancer.

Authors:  Hsuan Yen; Hsi Yen; Aaron M Drucker; Jiali Han; Wen-Qing Li; Tricia Li; Abrar Qureshi; Eunyoung Cho
Journal:  J Dtsch Dermatol Ges       Date:  2022-01-27       Impact factor: 5.231

6.  Potential risk factors for cutaneous squamous cell carcinoma include oral contraceptives: results of a nested case-control study.

Authors:  Maryam M Asgari; Jimmy T Efird; E Margaret Warton; Gary D Friedman
Journal:  Int J Environ Res Public Health       Date:  2010-02-03       Impact factor: 3.390

7.  Aspirin for the primary prevention of skin cancer: A meta-analysis.

Authors:  Yun Zhu; Yang Cheng; Rong-Cheng Luo; Ai-Min Li
Journal:  Oncol Lett       Date:  2015-01-07       Impact factor: 2.967

8.  Juglanin ameliorates UVB‑induced skin carcinogenesis via anti‑inflammatory and proapoptotic effects in vivo and in vitro.

Authors:  Gui-Rong Hou; Kang Zeng; Hai-Mei Lan; Qi Wang
Journal:  Int J Mol Med       Date:  2018-03-29       Impact factor: 4.101

Review 9.  The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors.

Authors:  Elena Campione; Evelin Jasmine Paternò; Eleonora Candi; Mattia Falconi; Gaetana Costanza; Laura Diluvio; Alessandro Terrinoni; Luca Bianchi; Augusto Orlandi
Journal:  Drug Des Devel Ther       Date:  2015-10-29       Impact factor: 4.162

10.  Juglanin administration protects skin against UVB‑induced injury by reducing Nrf2‑dependent ROS generation.

Authors:  Ying-Hui Kong; Su-Ping Xu
Journal:  Int J Mol Med       Date:  2020-04-24       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.